Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Macy's Inc (M) Price & Performance

Bristol-Myers Squibb CoTrade
Macy's IncTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Macy's Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.75 (market cap $132.45B), while Macy's Inc trades at $24.57 (market cap $6.68B). The key difference: Bristol-Myers Squibb Co is far larger — about 19.8× Macy's Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.

BMYM
Market Cap
$132.45B$6.68B
Sector
HealthConsumer Cyclical
52-Week High
$65.89$26.21
52-Week Low
$42.60$12.73
Enterprise Value
$166.44B$10.50B
Dividend Yield
3.89%3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.

BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.

Macy's Inc

Macy's (M) trades at $25.40, up 1.07% daily, with a bullish technical signal and positive earnings momentum after beating estimates in three consecutive quarters. The stock shows attractive valuation with a P/E of 10.5 and P/S of 0.31, while recent news highlights institutional buying and turnaround progress under the 'Bold New Chapter' strategy.

Outlook is cautiously optimistic with potential upside to the $30 analyst high target, supported by cost discipline and store revamps. Risks include competitive retail pressures and consumer spending volatility, but solid cash flow and low debt provide stability. The stock offers value with a 2.94% net margin and 14.36% ROE.

Returns comparison

Trailing returns across standard periods

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Macy's Inc

Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.

Read more on M